Description
VEGFR2, also known as kinase insert domain receptor (KDR), is a receptor tyrosine kinase that has roles in vascular permeability, cell proliferation and survival, and angiogenesis.1 It is composed of an N-terminal extracellular ligand-binding domain, which contains seven immunoglobulin-like (Ig-like) domains, a transmembrane domain, and an intracellular tyrosine kinase domain, which is subject to phosphorylation and contains a kinase insert domain and the C-terminal domain.1,2 VEGFR2 is expressed primarily in vascular and lymphatic endothelial cells, where it is bound by the growth factors VEGF-A, VEGF-C, and VEGF-D.1 Upon ligand binding, VEGFR2 forms homodimers or heterodimers with VEGFR1 or VEGFR3, resulting in VEGFR2 phosphorylation and activation of a variety of intracellular signaling pathways, including the ERK/MAPK pathway, to promote endothelial cell survival, proliferation, and migration. VEGFR2 also exists in a soluble form that is generated by alternative splicing of the KDR pre-mRNA or proteolytic shedding and decreases angiogenesis by functioning as a decoy receptor for VEGF-A.3,4 VEGFR2 expression is increased in the tumor vasculature of patients with a variety of solid tumors, including colorectal, lung, pancreatic, and breast cancer.5 Cayman’s VEGFR2 Rabbit Monoclonal Antibody (Clone RM515) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.WARNING This product is not for human or veterinary use.
